Coronavirus (COVID-19)
Learn more
Randomized, OpenLabel, Phase 3 Trial of Nivolumab Plus Ipilimumab or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Early Stage NSCLC
The purpose of this study is to determine the safety and effectiveness of nivolumab plus ipilimumab or nivolumab plus chemotherapy compared to chemotherapy alone in the treatment of Early Stage Non-Small Cell Lung. This study has multiple primary endpoints. The first primary completion date of Pathological Complete Response is anticipated to be reached September 2020. The completion date for all primary outcome measures is expected May 2023.
Eligibility Criteria:
This study is for patients age 18 and older.
Available at: Hospital of Central Connecticut
Get the latest healthcare news directly in your inbox.
Sign up for text alerts / Text MoreLife to 31996.